Dr. Reddy's Laboratories Ltd. NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1264.40 18.30 (1.47%)

1.7M

NSE+BSE Volume

NSE 10 Oct, 2025 3:31 PM (IST)

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1278.56. The consensus estimate represents an upside of 1.12% from the last price of 1264.40. View 18 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	11 Oct 2025	Dr. Reddy's Labs	Consensus Share Price Target	1264.40	1288.21	-	1.88	hold	pdf Detailed Estimates
	01 Feb 2024	Dr. Reddy's Labs	BOB Capital Markets Ltd.	1264.40	5900.00	5993.15 (-78.90%)	Target met	Hold	pdf post cache		Broker Report First Light \| Maruti Suzuki, Dr Reddy's Labs, Voltas, Dixon Technologies, Kajaria Ceramics, Blue Star, KEC … BOB Capital Markets Ltd. MSIL: Healthy all-round performance raise to BUY. DRRD: Buoyant US sales drive performance. VOLT: UCP improving, Qatar business a dampener. DIXON: Mobile business dials up growth; maintain BUY. KJC: Soft demand, intense competition mar quarter. BLSTR: Purple patch continues; maintain BUY. KECI: Pipeline robust, margin improvement delayed. ABSLAMC: Double-digit growth but market share bleed continues. Metals & Mining: Jindal Stainless: Management meet takeaways pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2024	Dr. Reddy's Labs	Axis Direct Target	1264.40	6000.00	6121.15 (-79.34%)	Target met	Hold	pdf post cache		Broker Report Result Update:Dr Reddys Labs Axis Direct We believe the company's strategy of investing in various businesses may provide growth in the long term. Recommendation: HOLD pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2024	Dr. Reddy's Labs	SMC online	1264.40		6121.15 (-79.34%)	Pre-Bonus/ Split	Results Update	pdf post cache		Broker Report Dr. Reddy Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2024	Dr. Reddy's Labs	Motilal Oswal Target	1264.40	5540.00	6121.15 (-79.34%)	Pre-Bonus/ Split	Neutral	pdf post cache		Broker Report NA/PSAI drive earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2024	Dr. Reddy's Labs	BOB Capital Markets Ltd. Target	1264.40	5900.00	6121.15 (-79.34%)	Target met	Hold	pdf post cache		Broker Report Dr Reddy's Labs (HOLD): Buoyant US sales drive performance BOB Capital Markets Ltd. Healthy quarter with revenue/PAT coming in 3%/4% ahead of consensus; US sales a positive surprise, rising 6% QoQ pdf Copy Link Share on Share on Share on Share on Alert
	30 Oct 2023	Dr. Reddy's Labs	SMC online	1264.40		5345.35 (-76.35%)	Pre-Bonus/ Split	Results Update	pdf post cache		Broker Report Dr. Reddy Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	30 Oct 2023	Dr. Reddy's Labs	Axis Direct Target	1264.40	5850.00	5345.35 (-76.35%)	Target met	Hold	pdf post cache		Broker Report Result Update:Dr Reddys Labs Axis Direct We believe the company's strategy of investing in various businesses may provide growth in the long term pdf Copy Link Share on Share on Share on Share on Alert
	30 Oct 2023	Dr. Reddy's Labs	BOB Capital Markets Ltd. Target	1264.40	5500.00	5345.35 (-76.35%)	Target met	Hold	pdf post cache		Broker Report Dr Reddy's Labs (HOLD): One-offs fuel PAT beat; India business still soft BOB Capital Markets Ltd. Q2 revenue in line but PAT outdid consensus by 22% on account of PLI benefits, litigation settlement and interest income pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2023	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1264.40	5300.00	5397.30 (-76.57%)	Target met	Sell	pdf post cache		Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	28 Oct 2023	Dr. Reddy's Labs	ICICI Securities Limited	1264.40	6000.00	5397.30 (-76.57%)	Target met	Accumulate	pdf post cache		Broker Report Cost pressure dents margins ICICI Securities Limited Dr. Reddy’s Laboratories’ (DRL) Q2FY24 gross and EBITDA margins were down 198bps/273bps YoY to 58.7%/28.9%, respectively. US price erosion, acquisition of Mayne Pharma and higher SG&A investments dented margins. pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners